Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Envveno Medical Corp
(NQ:
NVNO
)
3.450
-0.040 (-1.15%)
Streaming Delayed Price
Updated: 10:58 AM EST, Nov 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Envveno Medical Corp
< Previous
1
2
3
Next >
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
October 31, 2024
Via
ACCESSWIRE
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
October 28, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 10, 2024
Via
Benzinga
BioMedNewsBreaks — enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public Offering
October 01, 2024
Via
Investor Brand Network
Crude Oil Rises; Onconetix Shares Spike Higher
September 27, 2024
Via
Benzinga
Exposures
Fossil Fuels
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing
September 03, 2024
Via
ACCESSWIRE
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
August 14, 2024
Via
ACCESSWIRE
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Friday's Intraday Session
September 27, 2024
Via
Benzinga
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected
September 27, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Dow Surges Over 100 Points; Costco Earnings Top Views
September 27, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
September 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 27, 2024
Via
Benzinga
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
June 25, 2024
Via
ACCESSWIRE
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
April 09, 2024
Via
ACCESSWIRE
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
March 15, 2024
Via
ACCESSWIRE
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
September 27, 2024
Via
Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
September 27, 2024
Via
Benzinga
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
September 26, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
September 26, 2024
Via
Benzinga
Recap: enVVeno Medical Q4 Earnings
February 29, 2024
Via
Benzinga
enVVeno Medical Corporation Announces Proposed Public Offering
September 26, 2024
Via
ACCESSWIRE
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
June 21, 2024
Via
ACCESSWIRE
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
June 17, 2024
Via
ACCESSWIRE
NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024
May 08, 2024
NVNO stock results show that enVVeno Medical beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024
Via
ACCESSWIRE
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
April 24, 2024
Via
ACCESSWIRE
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
March 06, 2024
Via
ACCESSWIRE
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
February 29, 2024
Via
ACCESSWIRE
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
February 20, 2024
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.